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This dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended doses (RDs) of
5-fluorouracil (5FU), folinic acid and oxaliplatin (FOLFOX) with concomitant radiotherapy in inoperable/metastatic oesophageal
squamous cell carcinoma or adenocarcinoma. Patients received three courses of LV5FU2 regimen (folinic acid 200mgm
 2, bolus
5FU 300–400mg/m
2, continuous infusion 5FU 400–600mgm
 2 on days 1 and 2) and escalating doses of oxaliplatin 50 to
100mgm
 2 on day 1 (FOLFOX). This regimen was repeated every 2 weeks, concomitant to a 50-gray radiotherapy per 5 weeks.
Three more cycles were delivered after completion of radiation therapy. Three to six patients were allocated to each of the five dose
levels until MTD was reached. Thirty-three patients were enroled and 21 had metastatic disease. Maximum tolerated dose was
oxaliplatin 100mgm
 2, and continuous infusion 5FU was 600mgm
 2day
  (level 5). The most common toxicities were neutropenia,
dysphagia and oesophagitis. The RDs were those of FOLFOX-4 regimen (oxaliplatin 85mgm
 2 and full doses of LV5FU2). The
overall response was 48.5%, including 12% complete response. Response rate on primary tumour was 62.9%. This FOLFOX-4
regimen was reasonably well tolerated and effective in inoperable/metastatic oesophageal carcinoma and warrants additional
investigation.
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Oesophageal cancer is the eighth most common cancer worldwide,
responsible for 462000 new cases in 2002, and the sixth most
common cause of death from cancer with 386000 deaths (Parkin
et al, 2005). Cancer of the oesophagus carries a poor prognosis
with 5-year survival rates of 19.6% in the United States (Ries et al,
2008) and 10% in Europe (Sant et al, 2003). In France, the
mortality rate is 90% (Bossard et al, 2007). According to the
Burgundy cancer registry, no improvement in management of
oesophageal cancer has been observed when two time periods
(1976–1990 and 1997–2002) were compared. In the more recent
period, only 29.6% of the patients underwent a curative resection,
which yielded a 3-year survival rate of 9.7% (Bouvier et al,
2006).
As established by the Radiation Therapy Oncology Group
(RTOG) 85-01 study, the actual standard of care for patients
presenting with inoperable disease at diagnosis or with contra-
indications to surgery is combined chemoradiotherapy. The
standard radiation dose is 50.4 gray (Gy) in 25 fractions with a
cisplatin/5-fluorouracil (5FU) regimen, two cycles being adminis-
tered during radiation therapy and two more cycles given after
completion of the radiotherapy (Cooper et al, 1999). After a
median of follow-up of 8 years, 22% of the patients who received
combined modality therapy were alive, compared to 0% in the
radiation alone arm at 3 years. However, cisplatin, especially in
combination with 5FU, is known to produce significant adverse
effects (Bleiberg et al, 1997). This was observed in the RTOG study
as 20% of the patients suffered from life-threatening toxicities and
40% had to stop the chemotherapy before having completed the
courses (Cooper et al, 1999). Safer and more efficient alternatives
are therefore needed. To improve survival, synergistic combina-
tions would be also interesting.
Oxaliplatin, a third-generation cisplatin analogue, is active in
several solid tumour types, including some cisplatin/carboplatin
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srefractory diseases. Folinic acid (FA) modulates the activity of 5FU
and improves the outcome in both colorectal and gastric cancers
(Machover et al, 1986; Johnson et al, 1991; Louvet et al, 1991; Rubin
et al, 1996). It has been added to 5FU in several studies on
oesophageal cancer with encouraging results (Highley et al,1 9 9 3 ;
Stahl et al, 1994; Roca et al, 1996). The FOLFOX regimen (oxaliplatin,
5FU and FA) has already been tested in patients with recurrent or
metastatic cancer of the oesophagus or cardia, and showed a
significant antitumour activity along with a favourable toxicity
profile (Mauer et al, 2005). A cohort of patients with oesophageal
cancer had been treated with oxaliplatin, protracted infusional 5FU
and radiotherapy in a National Cancer Institute (NCI) phase I study
(Khushalani et al, 2002). This chemoradiotherapy regimen seemed to
be effective and less toxic than cisplatin given in combination with
5FU and radiotherapy. Given these results, it is of interest to assess
the tolerance and activity of chemoradiation using oxaliplatin in
locally advanced and metastatic oesophageal carcinomas using a
more convenient schedule. The aim of the study was to determine
the dose-limiting toxicity (DLT) during chemoradiotherapy, the
maximum tolerated dose (MTD), and the recommended doses (RDs)
for future phase II studies.
PATIENTS AND METHODS
Patient selection
Eligible patients were required to meet all of the following criteria:
locally advanced (tumour length X5cm) or metastatic adeno-
carcinoma, squamous cell or adenosquamous carcinoma of the
oesophagus; aged 18–75 years; Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0 2; not suitable for
oesophageal resection according to a multidisciplinary team; no
prior chemotherapy or chest irradiation; length of radiotherapy field
p30cm; peripheral neuropathy pgrade 1 NCI common terminology
criteria (CTC) version 2.0 (NCI); sufficient calorific intake;
adequate bone marrow function (absolute neutrophil count (ANC)
X2 10
9l
 1, platelet count X100 10
9l
 1), normal renal and liver
function. Patients were excluded if they were presenting small cell or
undifferentiated carcinoma of the oesophagus, complete dysphagia,
weight loss 420% of normal body weight, history of prior
malignancies (other than cured non-melanoma skin cancer, cured
cervical carcinoma in situ or stage I or II node-negative head-and
neck cancer cured more than 3 years ago), prior neck radiotherapy
with field overlapping the proposed oesophageal radiotherapy field,
brain or leptomeningeal metastases, tracheo–oesophageal fistula or
biopsy-proven invasion of the tracheo–bronchial tree. The study was
designed according to the Committee for Proprietary Medicinal
Products (CPMP) guideline for anticancer therapy (EMEA, 2003),
and conducted in accordance with the Declaration of Helsinki
(Declaration of Helsinki), Good Clinical Practice guidelines and
applicable local legal requirements. The protocol was approved by
the Ethical Committee of Lorraine. Written informed consent was
obtained from all patients.
Pretreatment evaluation
Screening assessments consisted of clinical history, recording of
concomitant medications, physical examination, ECOG perfor-
mance status, haematological and biochemical parameters and
electrocardiogram. Disease extension was assessed by oesophago-
scopy and biopsies, chest radiography, barium oesophagram, chest
and abdominal computed tomography (CT) and transoesophageal
ultrasonography (if possible).
Radiotherapy
External beam radiation therapy was delivered by linear accel-
erator using an energy 46MV. Three or four beams were used,
according to the dosimetry. All fields were treated each day. A total
dose of 50Gy in 25 fractions was prescribed at the ICRU reference
point, delivered 5 days a week. For the first plan, 40Gy was
delivered to the PTV, defined as the GTV with a 5-cm margin in
the cranio–caudal direction and 3cm radially, using custom
blocks. The primary tumour and regional lymph nodes were
included in this initial volume. A 10-Gy boost was then delivered to
a reduced volume (primary tumour and nodes with a 1-cm
margin). The maximum dose to the spinal cord was 40Gy. Portal
images for each field were performed at the initiation and at
the completion of radiotherapy.
Chemotherapy and study design
Three FOLFOX cycles were administered every 2 weeks during
the 5 weeks of the radiotherapy course. Then, in the absence of
tumour progression and/or limiting toxicity, three more cycles
were also administered. Metastatic patients who had stable
disease or objective response after radiotherapy were to continue
to receive FOLFOX every 2 weeks until limiting toxicity, lack
of clinical benefit, refusal or disease progression. Patients received
the following medications during each chemotherapy cycle:
oxaliplatin X mgm
 2 as a 2h i.v. infusion, on day 1; FA
200mgm
 2 i.v. infusion over 2h (concomitantly to oxaliplatin
on day 1 and alone on day 2); 5FU bolus Y mgm
 2day
 1 10min
i.v. bolus, following FA administration on days 1 and 2; 5FU Z
mgm
 2day
 1 22h i.v. continuous infusion, following 5FU bolus
administration on days 1 and 2. The dose levels of the escalation
design are described in Table 1. Oxaliplatin dose was reduced of
one level in case of grade 3 neutropenia with fever and/or infection
or grade 4 neutropenia, in case of grade 3–4 thrombopenia or
grade 2 neurotoxicity. The 5FU bolus was not administered in
the event of a grade 3–4 diarrhoea or mucositis/oesophagitis.
Three to six patients were allocated to each dose level until MTD
was reached. Three patients at a given dose level were to complete
the radiation therapy before patients were included at next dose
level. The MTD was defined as the dose level at which at least three
out of three or six patients experienced a DLT. If at least three out
of six patients had DLT at a given dose level, six patients were
included at the previous dose level. Each dose escalation was
discussed between the investigators, coordinator and sponsor. The
RD level was the dose level where two or less patients out of six
had a DLT.
Endpoints
The primary objective of the study was to document the MTD of
dose-escalated FOLFOX, when given with concomitant radio-
therapy for inoperable advanced or metastatic oesophageal cancer
treatment. The DLT was defined as any of the following event
occurring during the concomitant chemoradiotherapy period; an
NCI-CTC grade 4 thrombocytopenia, a febrile grade 4 neutropenia,
a grade 4 leucopoenia, a neutropenia leading to 47 days of
interruption of radiotherapy, or any grade 3–4 non-haematological
Table 1 FOLFOX (5-fluorouracil (5FU), folinic acid and oxaliplatin) dose
levels
Dose
level
a
Oxaliplatin
Xm gm
 2
Bolus 5FU
Ym gm
 2day
 1
Continuous infusion
5FU Z mgm
 2day
 1
1 50 300 400
2 50 400 600
3 75 400 600
4 85 400 600
5 100 400 600
aAll dose levels also included a 200mgm
 2 folinic acid i.v. infusion.
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stoxicity attributed to concomitant chemoradiotherapy (except
oesophagitis, dysphagia, nausea and vomiting). Patients must have
received a minimum of three cycles of chemotherapy and 40Gy
over a maximum of 6 weeks to be considered evaluable for
response, unless early disease progression occurred.
The secondary objectives were to determine the tumour
response rates using the World Health Organisation (WHO)
criteria, the duration of response for complete or partial
responders (CR or PR), the progression-free survival (PFS), the
overall survival and the degree of relief of dysphagia. Patients were
restaged 8 weeks after the completion of radiotherapy, and then, in
patients achieving a CR every 3 months until progression. All
lesions (primary tumour, involved nodes and metastases) had to
be assessed with CT scan, barium esophagram and endoscopy.
Patients with metastatic disease had a tumour evaluation after
every four cycles of chemotherapy. All objective responses were
confirmed by a second evaluation after 4 weeks. The duration of
response was defined as the time from the beginning of treatment
(for PR) or from the time of CR documentation to the time of the
documented progression. Toxicity was graded weekly during the
whole treatment (concomitant chemoradiotherapy and subsequent
chemotherapy) according to the NCI-CTC version 2.0 (NCI) and
specific neurotoxicity scale. All patients who received at least one
dose of chemotherapy were considered as evaluable for safety.
Dysphagia was graded at each visit to assess symptomatic relief.
Progression-free survival was calculated from the start of
treatment until death, cutoff date or date of the last follow-up
visit. Overall survival was measured from the initiation of the
treatment to the time of death, the date of the last follow-up visit or
the cutoff date.
Statistical analysis
The primary efficacy endpoint and response rates were assessed
based on both the intent-to-treat (ITT) and the evaluable per
protocol (PP) populations. All other endpoints were performed on
the ITT population. PFS and overall survival were estimated using
the Kaplan–Meier method.
Follow-up
During radiotherapy, symptoms, physical examination and haema-
tologic parameters were recorded weekly. In the case of grade 3–4
neutropenia or thrombocytopenia, complete blood counts were
performed twice a week until recovery to pgrade 2. The clinical
follow-up (as described above) was then performed every 2 weeks
Analysis
Follow-up
  5   4   3   2   1
(n)
Registered / treatment allocation 
Ineligible   - - - 1
7 6 7 7 6 33 
7 6 7 7 6 33 
1- 1226
653442 2
123231 1
22- 116
21- - - 3
---1 -1
1- - - - 1
114321 1
1
Received at least one dose of the 
allocated treatment 
Completed less than three cycles
Completed six cycles + radiation
Dose allocation  
Total
Total
Total
  5   4   3   2   1 Dose level
Dose level
Dose level
(n)
Discontinued prematurely
  - Adverse event
  - Disease progression
  - Investigator’s decision
  - Other (treatment interruption 
                > 2 weeks) 
  - Deaths (because of 
    adverse event)
Assessed for eligibility / registered 
(n= 33)
  5   4   3   2   1
(n)
  3 3   6   7   7   6   7 T T I
  9 2   5   6   6
1
1
7
  6   6
4
4
1 1 - 1
3 1 - 1
33 6 7 6 7
  PP analysis
Excluded from PP analysis 
- Less than three cycles with no 
early progression 
- Less than < 40 Gy over 
6 weeks 
Analysed for toxicity
analysis
Figure 1 Diagram of the study. ITT¼intent-to-treat; PP¼per protocol.
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swith complete blood counts assessed weekly and up to 8 weeks
after completion of radiation therapy. Patients were restaged
8 weeks after completion of radiotherapy and were then observed
every 3 months. Dysphagia grade was assessed 4 weeks after the
end of radiotherapy, and thereafter every 3 months until disease
progression using NCI-CTC criteria.
RESULTS
Patient characteristics
Between March 2000 and October 2004, 33 patients were enroled
in seven French institutions. One patient included in the level 5
cohort was subsequently considered as ineligible for DLT analysis
because of the baseline tracheal invasion. However, he remained
assessable for safety. He was not replaced as the MTD had already
been reached. The safety and ITT sets included 33 patients, and the
PP set 29 patients (Figure 1). Main baseline characteristics are
listed in Table 2.
Treatment delivered
Overall, the median number of cycles received was 6 (range: 1–10
cycles), with 19 patients (57.6%) having received X6 cycles. Dose
intensity, relative dose intensity, dose at first cycle and dose at last
cycle data were all similar among all the dose levels, for both
oxaliplatin and 5FU. Twenty patients (60.6%) had a treatment
delay (only one cycle in 16 cases). Of the 31 patients who received
at least two cycles, six patients (19.4%) had an oxaliplatin dose
reduction, six (19.4%) patients had a single 5FU dose reduction
and one patient had two 5FU dose reductions. The main reasons
for either cycle delays or dose reductions were the apparition of
haematological toxicities.
Maximum tolerated dose and dose-limiting toxicities
The number of patients who experienced DLTs and the type of
DLTs are provided in Table 3. The MTD was reached at dose level
5, where three out of five patients experienced DLTs (grade 3
asthenia, grade 4 asthenia and grade 3 diarrhoea). The majority
of DLTs was of grade 3, occurring mainly at cycle 3. All but one
DLT (a grade 4 febrile neutropenia) were grade 3–4 non-
haematological toxicities. The main observed toxicities at each
level for concomitant chemoradiotherapy and all cycles of
chemotherapy are summarised in Table 4.
Efficacy
Tumour responses are described in Table 5. Sixteen (48.5%; 95% CI:
30.8–66.5) patients showed a response to the treatment (CR or PR),
with four (12.1%) patients having a CR. The overall response rate
(among the 26 assessable patients) was 61.5%. Out of the
12 patients with locally advanced disease, 3 CR and 5 PR (66.6%)
were observed. None of these patients had secondary surgery.
Primary tumour response to chemoradiotherapy was assessed in 27
patients. Objective responses were observed in 17 patients (62.9%),
including six patients (22.2%) with CR. For all patients, the median
duration of response was 11.8 months (95% CI: (9.0; –)) and median
PFS was 6.7 months (95% CI: (4.3; 24.1)). Figure 2 presents the
overall survival. Median survival was 9.5 months (95% CI: (5.8;
16.0)). At 15 months, five patients with metastatic disease and seven
patients with locally advanced tumour were still alive.
Adverse events
Seven (21.8%) patients died during the treatment period. One
patient died from toxicities considered as related to study
treatment (level 2). This patient had a medical history of heavy
smoking, coronary insufficiency and obesity. He had metastases in
the lung and bilateral paratracheal metastatic nodes. Six weeks
Table 2 Patient characteristics (ITT population)
Total (n)3 3
Age (years)
Mean (s.d.) 58.2 (9.20)
Range 37–75
Gender (n, %)
Male 26 (78.8)
ECOG performance status (n,% )
0 5 (14.7%)
1 27 (79.4%)
2 2 (5.9%)
Stage (n,% )
III 12 (36.4)
IV 21 (63.4)
Dysphagia grade (n,% )
1 9 (27.2)
2 20 (60.6)
3 4 (12.1)
Histologic type (n,% )
Adenocarcinoma 10 (30.3)
Squamous cell 20 (60.6)
Mixed 3 (9.1)
Site of distant metastases (n¼21; n,% )
Lung 6 (28.5)
Lymph nodes 20 (95.2)
Liver 7 (33.3)
Peritoneum 1 (4.7)
Stage III¼T3 N1 M0 or T4 N0 or 1 M0; Stage IV¼any T any N M1.
Table 3 Number of patients with dose-limiting toxicity (DLT) by dose level
Dose level 1 (n¼6) 2 (n¼6) 3 (n¼6) 4 (n¼7) 5 (n¼5) Combined (n¼30)
Number of patients with DLT 2 1 2 1 3 9
Number of DLTs 3 2 3 1 3 12
Type of DLT
Anorexia 1 1 1 1 — 4
Asthenia 1 — 1 — 2 4
Epithelitis 1 — — — — 1
Febrile neutropenia — — 1 — — 1
Infection — 1 — — — 1
Diarrhoea — — — — 1 1
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safter the sixth course of chemotherapy, the patient experienced
acute respiratory failure and the chest X-rays showed diffuse
alveolo–interstitial pneumopathy, leading to his death. The
investigator considered that the death might be related to a
delayed pulmonary toxicity because of radiotherapy.
Oesophagitis was the most commonly experienced serious
adverse events (six patients; 18.2%). Nineteen patients experienced
toxicities that led to definitive or temporary treatment disconti-
nuation. The most common toxicities that led to treatment
discontinuation were asthenia (five patients) and oesophagitis
(four patients). Fifteen patients ceased the treatment because of a
toxicity considered to be related to the experimental chemotherapy
regimen (relationship likely or unknown). One patient developed
an acquired oesotracheal fistula at the upper pole of an oeso-
phageal prosthesis after the eighth course of chemotherapy. The
investigator considered that the fistula was related to a traumatism
because of oesophageal prosthesis.
No obvious differences between dose levels were observed with
regard to the frequency of deaths, other serious adverse events and
discontinuations related to adverse events.
Assessment of dysphagia
Four weeks after the completion of concomitant chemoradio-
therapy, dysphagia was described in 19 patients (59.4%), with
symptom improving with time. At 15 months, no residual
dysphagia was observed in the surviving patients.
DISCUSSION
The primary objective of this phase I study was to document the
MTD and RDs of a dose-escalated combination therapy containing
FOLFOX with concomitant radiotherapy as a first-line treatment
for inoperable advanced or metastatic oesophageal cancer.
Maximum tolerated dose was reached at dose level 5, where three
out of five patients experienced DLTs. The RD was therefore
dose level 4 (85mgm
 2 i.v. oxaliplatin, 200mgm
 2 i.v. FA,
400mgm
 2day
 1 bolus 5FU and 600mgm
 2day
 1 22-h infused
5FU), which is a full-dose FOLFOX 4 regimen (de Gramont et al,
2000). A major advantage of this treatment is that it can be safely
given on an outpatient basis. Approximately half of the patients
(48.5%) had an objective tumour response with associated relief of
dysphagia. Response rate appears to be higher on the primary
tumour site (62.9%). The lower median survival time in this study,
when compared to the other chemoradiation studies (Cooper et al,
1999; Minsky et al, 2002), most probably reflects the choice of our
inclusion criteria (metastatic disease or inoperable tumour
X5cm). The incidence of dose reduction because of toxicity was
low for both oxaliplatin and 5FU. Grade 3–4 haematological
toxicities were rare, for both oxaliplatin and 5FU and decreased
as the study progressed, indicating that these toxicities did not
worsen with continued administration of the experimental
treatment.
A prior phase I study combined oxaliplatin, protracted infusion
5FU and radiation in a preoperative setting (Khushalani et al,
2002). Forty patients received oxaliplatin (dose range:
85–100mgm
 2) on days 1, 15 and 29 and continuous infusion
5FU (dose range: 160–200mgm
 2day
 1) from days 8–42,
concurrently with a total radiotherapy dose of 50.4Gy. Most of
the patients (85%) had adenocarcinoma. Thirteen (32/5%) patients
underwent curative surgery. A pathologic complete response (pCR)
rate of 38% was observed. Therefeore, the RD was oxaliplatin
85mgm
 2, protracted infusion 5FU 180mgm
 2 along with radio-
therapy 50.4Gy in 28 fractions of 1.86Gy per fraction. A
retrospective series of 42 patients who received this regimen
observed a 25% pCR rate out of 20 patients undergoing surgery
(O’Connor et al, 2007). There was only one CR out of 13 patients
treated with definitive chemoradiation. The Southwest Oncology
Group phase II study in potentially curable stage II or III
oesophageal adenocarcinoma is currently ongoing. Another phase
I trial was conducted, using the combination of oxaliplatin,
cisplatin and protracted infusion 5FU associated with a standard
radiotherapy dose of 50.4Gy (Maurel et al, 2005). Nineteen patients
were treated and two pCR were observed in 12 patients who
underwent surgery. Toxicity was mild and a prospective phase II
study was planned for resectable oesophageal and gastric cancers.
Table 4 Grade 3–4 toxicities at various dose levels of oxaliplatin and
5FU (all cycles)
Dose level
1
(n¼7)
2
(n¼6)
3
(n¼7)
4
(n¼7)
5
(n¼6)
Combined
(n¼33)
Toxicity (NCI-CTC; n)
Haemoglobin — 1 1 — 3 5
W B C 1151 — 8
Granulocytes 1 2 5 1 — 9
Platelets — — 1 1 1 3
Febrile neutropenia — 1 1 — — 2
Anorexia 1 1212 7
Asthenia 1 — 2 1 3 7
Cough — — — — 2 2
Dehydration 1 — — 1 — 2
Diarrhoea — — — 1 1 2
Dysphagia 3 2432 1 4
Dyspnoea — — 1 — 1 2
Haemorrhage 1 1 — — — 2
Mucositis — 1 1 — — 2
Nausea 1 — — 1 — 2
Vomiting 1 — — 1 — 2
Oesophagitis 2 1 2 2 — 7
Pain — — 1 — 1 2
Septic shock — — 1 1 — 2
Neurotoxicity — 1 — — — 1
Table 5 Tumour responses on all disease sites
Dose level
1
(n¼7)
2
(n¼6)
3
(n¼7)
4
(n¼7)
5
(n¼6)
Combined
(n¼33)
Response (n)
Not evaluable 3 — 1 2 1 7
Complete response 2 — 2 — — 4
Partial response — 4332 1 2
Stable disease — 1 1 1 — 3
Progression 2 1 1 3 7
Number of responses 2 4532 1 6
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Figure 2 Overall survival. Censored values are presented with a triangle.
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sThe combination of oxaliplatin and capecitabine has recently
been tested in patients with advanced or metastatic oesophageal
cancer, mainly adenocarcinoma (88%). The response rate was
39% and the median survival time was 8 months (van Meerten
et al, 2007). In the phase III trial, REAL 2 comparing oxaliplatin
to cisplatin and capecitabine to 5FU, 964 eligible patients with
advanced oesophageal or gastric cancers were randomised
(Cunningham et al, 2006). Oesophageal and oesophagogastric
junction tumours represented 34.5 and 25.7% of the primaries. The
authors conclude that capecitabine may replace 5FU and
oxaliplatin may replace cisplatin for the treatment of advanced
oesophagogastric cancer.
This study suggests that further investigations are required in a
phase II study using the recommended dose level 4, the FOLFOX 4
regimen. Such a phase II–III randomised study is ongoing; it
compares chemoradiotherapy with FOLFOX 4 regimen (ie, dose
level 4 of this study) vs chemoradiotherapy with 5FU/cisplatin
(RTOG regimen) as a first-line treatment for patients with
inoperable oesophageal cancer. In conclusion, oxaliplatin, 5FU
and FA with concomitant radiotherapy (50Gy) is feasible and
effective in patients with inoperable locally advanced or metastatic
oesophageal cancer.
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